JP2021512614A5 - - Google Patents
Info
- Publication number
- JP2021512614A5 JP2021512614A5 JP2020542380A JP2020542380A JP2021512614A5 JP 2021512614 A5 JP2021512614 A5 JP 2021512614A5 JP 2020542380 A JP2020542380 A JP 2020542380A JP 2020542380 A JP2020542380 A JP 2020542380A JP 2021512614 A5 JP2021512614 A5 JP 2021512614A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- seq
- adhesion receptor
- target cell
- receptor
- Prior art date
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862628797P | 2018-02-09 | 2018-02-09 | |
| US62/628,797 | 2018-02-09 | ||
| US201862736965P | 2018-09-26 | 2018-09-26 | |
| US62/736,965 | 2018-09-26 | ||
| PCT/IB2019/000141 WO2019155286A2 (en) | 2018-02-09 | 2019-02-07 | Adhesion receptor constructs and uses thereof in natural killer cell immunotherapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021512614A JP2021512614A (ja) | 2021-05-20 |
| JP2021512614A5 true JP2021512614A5 (https=) | 2022-02-09 |
| JPWO2019155286A5 JPWO2019155286A5 (https=) | 2022-02-09 |
Family
ID=67548047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542380A Pending JP2021512614A (ja) | 2018-02-09 | 2019-02-07 | ナチュラルキラー細胞免疫療法における接着受容体構築物及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210054409A1 (https=) |
| EP (1) | EP3749686A4 (https=) |
| JP (1) | JP2021512614A (https=) |
| CN (1) | CN111712516A (https=) |
| AU (1) | AU2019219452A1 (https=) |
| CA (1) | CA3089167A1 (https=) |
| SG (1) | SG11202007183PA (https=) |
| WO (1) | WO2019155286A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015259877B2 (en) | 2014-05-15 | 2021-02-25 | National University Of Singapore | Modified natural killer cells and uses thereof |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| KR102660336B1 (ko) | 2017-03-27 | 2024-04-26 | 내셔널 유니버시티 오브 싱가포르 | 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도 |
| MX2019011570A (es) | 2017-03-27 | 2019-11-18 | Nat Univ Singapore | Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales. |
| AU2019219454A1 (en) | 2018-02-09 | 2020-08-27 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| CN112055717B (zh) | 2018-04-02 | 2024-04-26 | 新加坡国立大学 | 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子 |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| US12590148B2 (en) | 2018-11-26 | 2026-03-31 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| CN110396131B (zh) * | 2019-08-23 | 2020-07-10 | 北京鼎成肽源生物技术有限公司 | 一种ErbB2单链抗体、靶向人ErbB2的嵌合抗原受体、重组载体、重组细胞和应用 |
| CA3150224A1 (en) | 2019-09-10 | 2021-03-18 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| CN115197326B (zh) * | 2022-06-27 | 2025-05-16 | 安徽医科大学第一附属医院 | 融合蛋白及其编码基因和重组载体以及它们的应用 |
| CN116554300B (zh) * | 2023-04-27 | 2023-10-24 | 湖北医药学院 | 一种能与艰难拟梭菌毒素TcdB相互作用的多肽及其应用 |
| CN120098148B (zh) * | 2025-05-09 | 2025-07-22 | 四川康德赛医疗科技有限公司 | 一种工程化巨噬细胞制备及抗纤维化的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| CA2782333C (en) * | 2009-12-02 | 2019-06-04 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use |
| EP2948544A4 (en) * | 2013-01-28 | 2016-08-03 | St Jude Childrens Res Hospital | CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES |
| AU2015259877B2 (en) * | 2014-05-15 | 2021-02-25 | National University Of Singapore | Modified natural killer cells and uses thereof |
| EP3157958B1 (en) * | 2014-06-18 | 2020-05-06 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Car-expressing nk-92 cells as cell therapeutic agents |
| WO2017027325A1 (en) * | 2015-08-07 | 2017-02-16 | Imaginab, Inc. | Antigen binding constructs to target molecules |
| EP4074731A1 (en) * | 2015-11-04 | 2022-10-19 | City of Hope | Chimeric antigen receptors targeting her2 |
| SG11201810640RA (en) * | 2016-06-08 | 2018-12-28 | Intrexon Corp | Cd33 specific chimeric antigen receptors |
| KR102660336B1 (ko) * | 2017-03-27 | 2024-04-26 | 내셔널 유니버시티 오브 싱가포르 | 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도 |
-
2019
- 2019-02-07 EP EP19750822.9A patent/EP3749686A4/en not_active Withdrawn
- 2019-02-07 US US16/967,888 patent/US20210054409A1/en not_active Abandoned
- 2019-02-07 CN CN201980011826.9A patent/CN111712516A/zh active Pending
- 2019-02-07 AU AU2019219452A patent/AU2019219452A1/en not_active Abandoned
- 2019-02-07 WO PCT/IB2019/000141 patent/WO2019155286A2/en not_active Ceased
- 2019-02-07 CA CA3089167A patent/CA3089167A1/en not_active Abandoned
- 2019-02-07 SG SG11202007183PA patent/SG11202007183PA/en unknown
- 2019-02-07 JP JP2020542380A patent/JP2021512614A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021512614A5 (https=) | ||
| JP7499813B2 (ja) | 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用 | |
| KR102952460B1 (ko) | Cd3 항체 및 그의 약제학적 용도 | |
| JP7029822B2 (ja) | 抗原特異的ｔ細胞及びその使用 | |
| CN112969476B (zh) | 多特异性蛋白分子 | |
| CN109963876B (zh) | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 | |
| JP2014518615A5 (https=) | ||
| RS58448B1 (sr) | Antitela protiv antigena matičnih ćelija specifičan za prostatu i njihova upotreba | |
| TW201934582A (zh) | 抗pd-1/抗her2天然抗體結構樣異源二聚體形式雙特異抗體及其製備 | |
| CN112830969B (zh) | 一种特异性结合人Claudin18.2的单克隆抗体及包含其的药物和试剂盒 | |
| JPWO2019155286A5 (https=) | ||
| Spillner et al. | Recombinant IgE antibody engineering to target EGFR | |
| Xing et al. | BiHC, a T-cell–engaging bispecific recombinant antibody, has potent cytotoxic activity against Her2 tumor cells | |
| Hayashi et al. | A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells | |
| TWI867218B (zh) | 靶向her2的抗原結合建構體及用途 | |
| RU2019104896A (ru) | Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и способы их использования | |
| Zhao et al. | Recombinant human monoclonal igA antibody against CEA to recruit neutrophils to CEA-expressing cells | |
| CN119894930A (zh) | 一种双特异性抗体及其应用 | |
| US12534518B2 (en) | Fusion protein comprising anti-mesothelin antibody, anti-CD3 antibody or anti-EGFR antibody, bispecific or trispecific antibody comprising same, and uses thereof | |
| JP2021520813A5 (https=) | ||
| WO2024027828A1 (en) | Multi-specific antibodies targeting a dimerizable tumor antigen and an immunostimulatory antigen | |
| WO2024037627A1 (zh) | 一种双特异性抗体及其应用 | |
| CN117586408A (zh) | 一种结合tnfr2和b7h3的双特异性抗体 | |
| CN121064335A (zh) | 结合ror1和cd3的双特异性抗体及其用途 | |
| CN120192422A (zh) | 双特异性抗体及其应用 |